As one of the largest health care practices in the country, Polsinelli attorneys work as a fully integrated practice to seamlessly partner with clients on the whole gamut of issues. We consider it our business to understand the opportunities and challenges that face the health care industry and, more importantly, our clients’ businesses. The firm has built a team that is made up of health care industry experts, including a mix of former in-house counsel at national health care institutions, the FDA, CMS and the Department of Justice.

Recognized as a leader in health care law, Polsinelli Health Care rankings include:

  • National Tier One ranking in Health Care Law by Best Law Firms, 2014-2025
  • Ranked as the 2018 "Law Firm of the Year" in Health Care by U.S. News & World Report for the second time in four years
  • Nationally ranked in Healthcare Law by Chambers USA: America’s Leading Lawyers for Business, including:
    • Healthcare: The Elite – Nationwide, 2015-2024
    • Privacy & Data Security: Healthcare Nationwide
    • 9 ranked offices
    • 26 ranked attorneys
  • Nationally ranked by the American Health Law Association (AHLA) consistently since 2016, including:
    • Largest health care law firm in the nation by AHLA, 2018, 2021-2022
    • Second-largest health care law firm in the nation by AHLA, 2016, 2017, 2019, 2020, 2023
  • Ranked as the third-largest health care law firm in the nation by Modern Healthcare, 2022

Health care has experienced more change in the past five years than in the past 50 years combined. Reimbursement models are shifting from fee for service to pay for quality. The line between payors and providers has blurred and, in some cases, disappeared. Telehealth has emerged as a common modality, and data has exploded. For example, the health care industry is generating approximately 30% of the world’s data volume today. Beyond data, health care is one of the biggest forces in the economy today. Health care spending accounted for over 19.7% of US GDP in 2020.

Providers are being asked to keep pace with these changes and meet these challenges within one of the fiercest enforcement environments they have ever faced. Failure to keep up with the barrage of changing regulatory requirements can have catastrophic consequences. The pandemic disrupted FDA rules for medical devices, diagnostics and pharmaceuticals, with implications for providers, investors, and device and drug companies.

Not surprisingly, private equity has taken a keen interest in the health care industry and has invested billions of dollars into health care ventures of ever-increasing complexity and higher risk profiles. This evolution has continued despite the emergence of the most significant pandemic in a century. In 2018, the valuation of private equity deals in the U.S. health care sector surpassed $100 billion — a twentyfold increase from 2000. These acquisitions spanned all subsectors, from physician practices to retail health and mobile application companies. Further, private equity investment closely aligns with emerging health care economic drivers, including service areas like behavioral health, home care and technology solutions made available to both consumers and providers.

We represent various clients in the health care industry, including:

  • Hospitals & Health Systems
  • Academic Medical Centers
  • Behavioral Health
  • Rural Health Providers
  • Dialysis
  • Home Health & Hospice
  • Infusion Therapy
  • Laboratories
  • Pharmacies
  • Medical Devices
  • Digital Health & Health Technology Companies
  • Private Equity in Health Care
  • Long Term Care
  • Assisted Living, Memory Care, Senior Housing
Publications
All Publications
Radiation Oncology Community Seeking Relief from an Emerging Crisis under 2026 Changes to Medicare Coding and Reimbursement
Reimbursement Declines Emerge Under 2026 Medicare Changes Stakeholders from the radiation oncology community are reporting substantial declines in aggregate reimbursement during the initial months of 2026 for radiation oncology services provided in hospital outpatient departments, freestanding cancer centers and physician practices throughout the United States. In addition to concerns about the fairness and adequacy of the 2026 payment levels, providers also report significant problems with some payors routinely denying and delaying payment for claims involving the recently redefined radiation oncology codes. Providers are describing challenges arising under Medicare, Medicaid and private insurers with the aggregate impacts of these challenges varying based on the location and payor mix of individual radiation oncology departments and practices. What Changed Under the 2026 Medicare Rules CMS finalized
Read More
Medspas on Alert: The FDA Says You’re a Dispenser Too
Key Takeaways Medspas and other entities operating in the aesthetic space that dispense or administer prescription drugs should assess whether they have obligations as dispensers under the DSCSA and ensure they have policies, procedures and controls in place to demonstrate compliance with applicable requirements. To avoid the deficiencies cited in the warning letter, dispensers should focus on strengthening supply chain controls, maintaining complete product records and ensuring operational readiness for FDA inspection. Dispensers that receive a Form FDA 483 documenting observations of potential violations after an FDA inspection should act immediately to develop a thorough response with supporting documentation. On April 1, 2026, the FDA issued a warning letter to Pure Indulgence Aesthetics (Pure Indulgence), a Texas-based medical spa. Notably, this is the first
Read More